943605-85-4

Basic information

• Product Name: 6-Bromo-7-methylquinazolin-4(3H)-one
• Synonyms: 6-Bromo-7-methylquinazolin-4(3H)-one;4(3H)-Quinazolinone, 6-broMo-7-Methyl-;6-Bromo-7-methyl-4(3H)-quinazolinone
• CAS NO: 943605-85-4
• Molecular Formula: C9H7BrN2O
• Molecular Weight: 239.06868
• EINECS: 604-604-1
• Mol File: 943605-85-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 450.6°C at 760 mmHg
• Flash Point: 226.3°C
• Appearance: /
• Density: 1.72±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 2.61E-08mmHg at 25°C
• Refractive Index: 1.693
• CAS DataBase Reference: 6-Bromo-7-methylquinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-7-methylquinazolin-4(3H)-one(943605-85-4)
• EPA Substance Registry System: 6-Bromo-7-methylquinazolin-4(3H)-one(943605-85-4)

Safety Data

• Hazardous Substances Data: 943605-85-4(Hazardous Substances Data)

Usage

General Description

6-Bromo-7-methylquinazolin-4(3H)-one is a chemical compound with the molecular formula C10H8BrN3O. It is a heterocyclic organic compound with a quinazolinone core structure. 6-Bromo-7-methylquinazolin-4(3H)-one is commonly used in pharmaceutical research and drug development due to its potential biological activities, such as antitumor, antiproliferative, and anticancer properties. It is also being studied for its potential use in the treatment of various diseases and conditions. 6-Bromo-7-methylquinazolin-4(3H)-one is synthesized through a series of chemical reactions and is available for purchase from chemical suppliers for research and industrial purposes.

InChI:InChI=1/C9H7BrN2O/c1-5-2-8-6(3-7(5)10)9(13)12-4-11-8/h2-4H,1H3,(H,11,12,13)

Upstream product

• 75844-40-5 7-methyl-quinazolin-4(3H)-one 
• 106976-24-3 2-amino-5-bromo-4-methylbenzoic acid 
• 77287-34-4 formamide 
• 39549-79-6 2-amino-4-methylbenzamide 
• 26830-96-6 5-methyl-2-cyanoaniline 

Downstream Products

• 943605-86-5 6-bromo-7-methyl-8-nitroquinazolin-4(3H)-one 
• 1446111-75-6 4-amino-N-(4-((4-chlorophenyl)amino)-7-methylquinazolin-8-yl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1446113-37-6 6-bromo-N-(4-chlorophenyl)-7-methyl-8-nitroquinazolin-4-amine 
• 1446113-38-7 N⁴-(4-chlorophenyl)-7-methylquinazoline-4,8-diamine 
• 1093101-65-5 8-amino-7-methylquinazolin-4(3H)-one 
• 1093101-48-4 4-(8-amino-7-methylquinazolin-4-ylamino)benzonitrile 
• 1093101-47-3 4-(6-bromo-7-methyl-8-nitroquinazolin-4-ylamino)benzonitrile 
• 1093100-62-9 N₈-(3-(9H-purin-6-yI)pyridin-2-yI)-N₄-(4-chIorophenyl)-7-methylquinazoline-4,8-diamine 
• 1093100-51-6 4-(8-(3-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyridin-2-ylamino)-7-methylquinazolin-4-ylamino)benzonitrile 
• 1093100-19-6 4-(8-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyridin-2-ylamino)-7-methylquinazolin-4-ylamino)benzonitrile 
• 1093100-21-0 4-(8-(3-(9H-purin-6-yI)pyridin-2-ylamino)-7-methylquinazolin-4-ylamino)benzonitrile 
• 1093100-60-7 N₈-(3-(9H-purin-6-yI)pyridin-2-yl)-N₄-(3-ethynylphenyl)-7-methylquinazoline-4,8-diamine 
• 1093100-61-8 N₈-(3-(9H-purin-6-yl)pyridin-2-yl)-N₄-(4-(difluoromethoxy)phenyl)-7-methylquinazoline-4,8-diamine 
• 1093100-56-1 N₈-(3-(9H-purin-6-yl)pyridin-2-yl)-7-methyl-N₄-(3-(trifluoromethyl)phenyl)quinazolin-4,8-diamine 

Relevant articles and documents

THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof

Substituted 4-amino-quinazoline compounds corresponding to formula I methods for their production, pharmaceutical compositions containing these compounds as active agents, and the uses thereof for treating or inhibiting disorders or disease states.

NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.